Abstract
This review article describes the identification of the tyrosine kinase BCR/ABL as the hallmark of chronic myeloid leukemias (CML) as well as the development of a specific inhibitor of this tyrosine kinase, the STI571 (Glivec, imatinib mesylate). The authors discuss the results of a phase I and three phase II trials reporting the efficacy of STI571 as treatment for CML patients and propose two simplified algorithms that may help to guide decision-making for the individual patient.
MeSH terms
-
Algorithms
-
Antimetabolites, Antineoplastic / therapeutic use
-
Antineoplastic Agents / therapeutic use
-
Benzamides
-
Clinical Trials, Phase I as Topic
-
Clinical Trials, Phase II as Topic
-
Cytarabine / therapeutic use
-
Enzyme Inhibitors / therapeutic use
-
Fusion Proteins, bcr-abl / antagonists & inhibitors
-
Hematopoietic Stem Cell Transplantation
-
Humans
-
Imatinib Mesylate
-
Interferon-alpha / therapeutic use
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
-
Piperazines / therapeutic use
-
Protein-Tyrosine Kinases / antagonists & inhibitors
-
Pyrimidines / therapeutic use
Substances
-
Antimetabolites, Antineoplastic
-
Antineoplastic Agents
-
Benzamides
-
Enzyme Inhibitors
-
Interferon-alpha
-
Piperazines
-
Pyrimidines
-
Cytarabine
-
Imatinib Mesylate
-
Protein-Tyrosine Kinases
-
Fusion Proteins, bcr-abl